The quick transition of free initial prescriptions to reimbursed product helped carry Amgen Inc.'s CGRP inhibitor Aimovig (erenumab) to $22m in third quarter sales, the firm reported Oct. 30, as payers agree more often than not to cover the cost of the migraine prevention therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?